Eloralintide (LY3841136) is an investigational amylin analogue from Eli Lilly and Company. It is not approved for any use. This page lists every eloralintide study on ClinicalTrials.gov, grouped by phase, with the status each registry record showed on 9 October 2026.
Read with care: a registry record describes a study’s plan and status. It is not a result, and it does not show that the drug works or is safe. This page is information only. It does not recruit participants and it is not medical advice. Whether anyone can join a study is decided by the sponsor and the study site, so use the official links below.
Studies at a glance
There are 22 registered studies that list eloralintide: 5 Phase 3, 5 Phase 2, 6 Phase 1 safety and combination studies, and 6 Phase 1 studies of how the body handles the compound. Twelve were recruiting on the check date, 2 were active but no longer recruiting, 1 had not yet started, and 7 were completed.
Phase 3: the ENLIGHTEN program
| Study | Registry number | Who it enrolls | Status | Enrollment | Start | Primary completion |
|---|---|---|---|---|---|---|
| ENLIGHTEN-1 | NCT07321886 | Obesity or overweight, without type 2 diabetes | Recruiting | 1,980 | Feb 2026 | Mar 2028 |
| ENLIGHTEN-2 | NCT07282600 | Obesity or overweight, with type 2 diabetes | Recruiting | 1,035 | Dec 2025 | Jan 2028 |
| ENLIGHTEN-3 | NCT07369011 | Obstructive sleep apnea with obesity or overweight | Recruiting | 800 | Feb 2026 | Mar 2028 |
| ENLIGHTEN-4 | NCT07353931 | Knee osteoarthritis pain with obesity or overweight | Recruiting | 900 | Feb 2026 | Mar 2028 |
| ENLIGHTEN-6 | NCT07392190 | Persistent obesity or overweight despite a weekly incretin | Recruiting | 900 | Feb 2026 | Jun 2028 |
Phase 2 studies
| Study | Registry number | Who it enrolls | Status | Enrollment | Start | Primary completion |
|---|---|---|---|---|---|---|
| 48-week Phase 2 study | NCT06230523 | Obesity or overweight | Completed | 263 | Feb 2024 | May 2025 |
| Phase 2 with tirzepatide | NCT06603571 | Obesity or overweight with type 2 diabetes | Completed | 367 | Sep 2024 | Jul 2026 |
| Macupatide and eloralintide, type 2 diabetes | NCT07215559 | Obesity or overweight with type 2 diabetes | Recruiting | 200 | Oct 2025 | Mar 2027 |
| Macupatide and eloralintide, no diabetes | NCT07589608 | Obesity or overweight without type 2 diabetes | Recruiting | 400 | May 2026 | Sep 2027 |
| Chronic weight management master protocol | NCT06143956 | Obesity or overweight (umbrella protocol) | Recruiting | 1,481 | Nov 2023 | Sep 2027 |
Phase 1: first-in-human and combination studies
| Study | Registry number | Who it enrolls | Status | Enrollment | Start | Primary completion |
|---|---|---|---|---|---|---|
| First-in-human | NCT05295940 | Healthy and overweight adults | Completed | 148 | Mar 2022 | Jan 2024 |
| Multiple-dose with tirzepatide | NCT06345066 | Overweight or obesity | Completed | 96 | Apr 2024 | Sep 2025 |
| Alone and with tirzepatide | NCT06916065 | Overweight or obesity | Completed | 188 | Apr 2025 | Jan 2026 |
| Japanese participants | NCT06297616 | Obesity or overweight (Japan) | Completed | 128 | Apr 2024 | Nov 2025 |
| Chinese participants | NCT06916091 | Obesity or overweight (single site, Singapore) | Completed | 30 | Apr 2025 | Sep 2025 |
| Macupatide combination, Japan | NCT07765511 | Obesity or overweight without diabetes (Japan) | Not yet recruiting | 60 | Oct 2026 (planned) | Jun 2027 |
Phase 1: how the body handles the compound
| Study | Registry number | Who it enrolls | Status | Enrollment | Start | Primary completion |
|---|---|---|---|---|---|---|
| Liver impairment | NCT07401862 | Mild to severe hepatic impairment and normal function | Recruiting | 36 | Feb 2026 | Mar 2027 |
| Kidney impairment | NCT07426380 | Severe renal impairment or end-stage kidney disease | Active, not recruiting | 28 | Feb 2026 | Oct 2026 |
| Gastric emptying | NCT07738614 | Obesity or overweight | Recruiting | 56 | Jul 2026 | Dec 2026 |
| Insulin sensitivity | NCT07665879 | Obesity or overweight | Recruiting | 115 | Jun 2026 | Aug 2027 |
| Two formulations compared | NCT07701083 | Healthy participants | Active, not recruiting | 58 | Jul 2026 | Oct 2026 |
| Oral contraceptive interaction | NCT07808060 | Women with obesity or overweight | Recruiting | 34 | Sep 2026 | Jun 2027 |
Enrollment figures for studies that have not finished are planned numbers. Dates are the registry’s own. Each registry number links to our plain-language record of that study, which links on to ClinicalTrials.gov.
How to check a study yourself
Search the registry for the NCT number at ClinicalTrials.gov. Each record shows the sponsor, status, eligibility rules, locations and a contact for the study team. Lilly also runs a trial finder for its own studies. Eligibility rules differ for each study and are set out in the record, and enrollment decisions are made by the study site.
Things to keep in mind when reading these records
Some studies run under one umbrella protocol (NCT06143956), so adding up enrollment across records double counts. A registry status of recruiting means the study as a whole is open, and individual sites can be paused or full. Completed Phase 1 studies often still show no posted results, which is normal and not a signal either way. The macupatide studies test a different Lilly compound together with eloralintide, and are covered on our macupatide page.
Where to read next
See the ENLIGHTEN Phase 3 program, the Phase 2 results, the Phase 1 studies and the approval status page.
Source: ClinicalTrials.gov registry records, searched for eloralintide and LY3841136 on 9 October 2026. Statuses change often. We re-check this page regularly and update the date when we do.